Animal and Organoid Model Core
动物和类器官模型核心
基本信息
- 批准号:10514322
- 负责人:
- 金额:$ 365.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAnimal ModelAnimal TestingAnimalsAntiviral AgentsArbovirus InfectionsCOVID-19COVID-19 pandemicCaviaCessation of lifeClinicCoronavirusDevelopmentDisease OutbreaksDrug KineticsEbola virusEconomicsEnvironmentEventExcretory functionFamilyFerretsFlavivirusFormulationFutureGoalsGrowthIn VitroInfectionIntravenousKineticsLeadLifeMedicalMedicineMesocricetus auratusMetabolismMiddle East Respiratory Syndrome CoronavirusModalityModelingMorbidity - disease rateMusOralOrganoidsOrthobunyavirusPathogenicityPathologicPharmaceutical ChemistryPhysiologicalProcessPropertyProteinsRNARNA InterferenceReadinessRouteSARS coronavirusSARS-CoV-2 infectionTestingTimeToxic effectUnited StatesVaccinesVariantViralVirusVirus DiseasesWorkabsorptionagedbaseefficacy studyguinea pig modelhemorrhagic fever virusin vivoin vivo evaluationinhibitorintraperitonealmortalitymouse modelnovelpandemic diseasepandemic preparednessprevent
项目摘要
SUMMARY
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), exploded into a global pandemic in late 2019 causing significant loss of life, pronounced economic
disruption and major long-term medical impacts which are still being characterized. The current COVID19
pandemic highlighted our severe lack of preparedness and, despite an effective vaccine being developed in
record time, the continued need for efficacious antiviral drugs to quell the morbidity and mortality associated with
infection became evident. Despite an accelerated push to identify and bring forward anti-viral medicines, few
made it to the clinic in time to prevent the approximately 700,000 deaths observed in the United States and
several million across the globe. Moreover, many emerging and re-emerging viral diseases with pandemic
potential have been identified which could bring similar or excess morbidity and mortality as COVID19 in a future
pandemic event. This pandemic highlights the need to get ahead of viruses with pandemic potential to be ready
for the next outbreak. As such, the goal of this proposal is to identify novel, direct-acting antivirals.
The broad, long-range objectives of the Animal and Organoid Model Core (Core D) are to develop/employ
organoid and animal models for testing of selected candidate anti-viral compounds generated in projects 1-6 of
this U19 application. The Animal and Organoid Model Core will work in conjunction with the project leaders
(projects 1-6), HTS core (Core A), medicinal chemistry core (Core B) and the absorption, distribution,
metabolism, excretion and toxicity (ADMET)/formulation core (Core C) to identify, modify and formulate
candidate hits for in vivo testing in the animal models. The primary goal will be the development of potent, orally
bioavailable direct acting antiviral compounds against specific Coronavirus, Flavivirus and Bunyavirus targets
described within this proposal.
概括
2019 年冠状病毒病 (COVID-19),由严重急性呼吸系统综合症冠状病毒 2 (SARS-
CoV-2)于 2019 年底爆发为全球大流行,造成重大生命损失,对经济造成显着影响
破坏和重大长期医疗影响仍在定性中。当前的新冠肺炎
大流行凸显了我们严重缺乏准备,尽管我们正在开发有效的疫苗
创纪录的时间,持续需要有效的抗病毒药物来降低与病毒相关的发病率和死亡率
感染变得明显。尽管加速推动抗病毒药物的识别和开发,但很少有人
及时到达诊所,避免了美国观察到的约 70 万人死亡,
全球有数百万人。此外,许多新出现和重新出现的大流行病毒性疾病
已确定未来可能带来与新冠病毒类似或过高的发病率和死亡率
流行病事件。这次大流行凸显了我们需要提前做好应对具有大流行潜力的病毒的准备
为了下一次的爆发。因此,该提案的目标是确定新型、直接作用的抗病毒药物。
动物和类器官模型核心(核心 D)的广泛、长期目标是开发/使用
用于测试项目 1-6 中产生的选定候选抗病毒化合物的类器官和动物模型
这个U19应用程序。动物和类器官模型核心将与项目负责人合作
(项目1-6)、HTS核心(Core A)、药物化学核心(Core B)以及吸收、分配、
代谢、排泄和毒性 (ADMET)/配方核心(核心 C),用于识别、修改和配制
用于动物模型体内测试的候选产品。主要目标是开发有效的口服药物
针对特定冠状病毒、黄病毒和布尼亚病毒靶标的生物可利用的直接作用抗病毒化合物
本提案中进行了描述。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Ross Teijaro其他文献
John Ross Teijaro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Ross Teijaro', 18)}}的其他基金
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
- 批准号:
10445313 - 财政年份:2021
- 资助金额:
$ 365.76万 - 项目类别:
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
- 批准号:
10316578 - 财政年份:2021
- 资助金额:
$ 365.76万 - 项目类别:
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
- 批准号:
10650747 - 财政年份:2021
- 资助金额:
$ 365.76万 - 项目类别:
Engineer Immune Cells via Chemoenzymatic Glycan Editing
通过化学酶聚糖编辑工程免疫细胞
- 批准号:
10350593 - 财政年份:2019
- 资助金额:
$ 365.76万 - 项目类别:
Engineer Immune Cells via Chemoenzymatic Glycan Editing
通过化学酶聚糖编辑工程免疫细胞
- 批准号:
10578671 - 财政年份:2019
- 资助金额:
$ 365.76万 - 项目类别:
IL-27 elicited antibodies: A novel means to control persistent Arenavirus infection
IL-27 引发抗体:控制持续性沙粒病毒感染的新方法
- 批准号:
9204389 - 财政年份:2016
- 资助金额:
$ 365.76万 - 项目类别:
Novel Strategies for Controlling Persistent Viral Infection
控制持续病毒感染的新策略
- 批准号:
9077410 - 财政年份:2016
- 资助金额:
$ 365.76万 - 项目类别:
Novel Strategies for Controlling Persistent Viral Infection
控制持续病毒感染的新策略
- 批准号:
9248857 - 财政年份:2016
- 资助金额:
$ 365.76万 - 项目类别:
The Role of IL-27 in Controlling Persistent Viral Infection
IL-27 在控制持续病毒感染中的作用
- 批准号:
8897666 - 财政年份:2014
- 资助金额:
$ 365.76万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 365.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists